Study guide
5.2 Peripheral Artery Disease & Acute Limb Ischemia
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
5.2 Peripheral Artery Disease & Acute Limb Ischemia
Key Takeaways Explain This Topic AI
Ankle-Brachial Index (ABI) is diagnostic for Peripheral Artery Disease: normal is 1.00-1.40, mild-moderate PAD is 0.41-0.90, severe PAD / critical limb ischemia is ≤0.40, and >1.40 indicates non-compressible calcified vessels requiring Toe-Brachial Index (TBI).
Intermittent claudication is exertional leg pain relieved by rest; ischemic rest pain occurs at night, is worsened by leg elevation, and is relieved by placing the limb in a dependent position.
Cilostazol is a PDE-3 inhibitor effective for claudication symptoms but is absolutely contraindicated in patients with heart failure of any severity.
Acute Limb Ischemia presents with the 6 Ps (Pain, Pallor, Pulselessness, Paresthesia, Paralysis, Poikilothermia) and requires immediate systemic heparinization followed by catheter-directed thrombolysis or surgical embolectomy.
Reperfusion of an acutely ischemic limb can precipitate compartment syndrome (requiring emergency 4-compartment fasciotomy) and systemic reperfusion injury (hyperkalemia, myoglobinuria, and acute tubular necrosis).
Last updated: August 2026
5.2 Peripheral Artery Disease & Acute Limb Ischemia
Peripheral Artery Disease (PAD) and Acute Limb Ischemia (ALI) represent systemic atherosclerotic and thromboembolic pathology affecting arterial perfusion to the extremities. Critical care cardiac nurses managing post-cardiac surgery patients, IABP/Impella access sites, or vascular admissions must quickly interpret Ankle-Brachial Index (ABI) values, recognize the '6 Ps' of acute ischemia, monitor catheter-directed thrombolysis, and detect life-threatening compartment syndrome.
Ankle-Brachial Index (ABI) Diagnostic Interpretation
The Ankle-Brachial Index (ABI) is the gold-standard bedside non-invasive diagnostic test for lower extremity PAD.
Calculation Method
Measure resting Systolic Blood Pressure (SBP) in both brachial arteries using a Doppler ultrasound probe.
Measure SBP in both the Posterior Tibial (PT) and Dorsalis Pedis (DP) arteries in each ankle.
Calculate ABI for each leg independently using the formula: ABI (per leg) = Highest ankle SBP (PT or DP) in that leg Highest brachial SBP of either arm \text{ABI (per leg)} = \frac{\text{Highest ankle SBP (PT or DP) in that leg}}{\text{Highest brachial SBP of either arm}} ABI (per leg) = Highest brachial SBP of either arm Highest ankle SBP (PT or DP) in that leg
ABI Value Clinical Classification Pathophysiology & Hemodynamics Recommended Clinical Management
> 1.40 Non-Compressible / Calcified Medial arterial calcification (Mönckeberg sclerosis) common in Diabetes and End-Stage Renal Disease; vessels resist compression. Perform Toe-Brachial Index (TBI) ; abnormal if TBI < 0.70.
1.00 – 1.40 Normal Intact, healthy arterial perfusion. Cardiovascular risk reduction.
0.91 – 0.99 Borderline Mild vascular compliance reduction; potential early atherosclerosis. Exercise testing / re-evaluate if symptomatic.
0.41 – 0.90 Mild to Moderate PAD Significant arterial stenoses; typically presents with classic intermittent claudication . Single antiplatelet agent, high-intensity statin, supervised exercise, Cilostazol.
≤ 0.40 Severe PAD / CLTI Critical Limb-Threatening Ischemia (CLTI); multi-level arterial occlusion; ischemic rest pain , tissue loss, gangrene. Urgent vascular surgical evaluation for revascularization (endovascular/bypass).
Clinical Features: Intermittent Claudication vs. Ischemic Rest Pain
Intermittent Claudication :
Characteristics : Reproducible muscle aching, cramping, pain, or fatigue in the calf, thigh, or buttock during physical exertion (walking).
Relief : Resolves completely within 2 to 10 minutes of standing still or resting.
Mechanism : Fixed arterial obstruction prevents necessary blood flow increases to meet skeletal muscle metabolic demand during exercise.
Ischemic Rest Pain (Critical Limb-Threatening Ischemia) :
Characteristics : Severe, burning, unremitting pain in the distal foot and toes.
Timing : Typically occurs at night when the patient is recumbent in bed (loss of gravity-assisted arterial flow).
Relief & Positional Dependency : Worsened by leg elevation ; relieved by dangling the leg over the edge of the bed or standing (dependent position).
Physical Exam : Dependent rubor (deep purplish-red discoloration when dangling) and elevation pallor (blanching when raised above heart level), non-healing arterial ulcers (punched-out appearance on toes/malleolus), loss of hair, thick brittle nails, diminished capillary refill.
Pharmacotherapy & Secondary Prevention in PAD
Antiplatelet Therapy :
Single agent antiplatelet: Aspirin 81 mg daily OR Clopidogrel 75 mg daily to reduce major adverse cardiovascular events (MACE) and stroke.
Dual Pathway Inhibition: Aspirin 81 mg daily + Low-Dose Rivaroxaban 2.5 mg BID (per the landmark COMPASS trial) for high-risk PAD patients to lower limb ischemic events and MACE.
High-Intensity Statin Therapy :
Atorvastatin 80 mg or Rosuvastatin 40 mg targeting LDL-C < 55 mg/dL (or at least 50% reduction). Statins stabilize plaque, improve walking distance, and reduce amputation risk.
Cilostazol (Pletal) :
Mechanism : Selective Phosphodiesterase-3 (PDE-3) inhibitor. Increases intracellular cAMP, resulting in direct arterial vasodilation and inhibition of platelet aggregation.
Dosing : 100 mg orally BID taken 30 minutes before or 2 hours after meals.
ABSOLUTE CONTRAINDICATION : CONTRAINDICATED IN PATIENTS WITH HEART FAILURE OF ANY SEVERITY . PDE-3 inhibitors (similar to milrinone) have been shown to increase mortality in patients with chronic heart failure.
Supervised Exercise Therapy (SET) :
Treadmill exercise program (30-45 minutes per session, 3 times/week for at least 12 weeks) pushing patients to moderate-to-severe claudication before resting; significantly improves collateral vessel development.
Acute Limb Ischemia (ALI): The 6 Ps & Rutherford Staging
Acute Limb Ischemia is a vascular emergency characterized by a sudden drop in limb perfusion (<14 days) threatening limb viability.
Etiologies
Embolic Occlusion : Abrupt onset, severe presentation. Source: Left atrium (Atrial Fibrillation), LV mural thrombus post-MI, prosthetic cardiac valves, or aortic atheroma.
Acute Thrombotic Occlusion : Subacute or acute presentation occurring at the site of pre-existing atherosclerotic plaque or vascular bypass graft failure.
The 6 Ps of Acute Limb Ischemia Clinical Manifestation & Nursing Assessment
1. Pain Severe, sudden onset continuous pain distal to the site of arterial occlusion; poorly responsive to opioids.
2. Pallor Pale, cadaveric, or mottled skin appearance; delayed capillary refill (>3-5 seconds).
3. Pulselessness Loss of palpable radial, femoral, popliteal, or pedal pulses; absent Doppler arterial signals.
4. Paresthesia Numbness, tingling, or diminished light touch sensation (indicates nerve ischemia; critical sign ).
5. Paralysis Inability to move toes or foot; loss of motor function (indicates advanced muscle/nerve death).
6. Poikilothermia Coolness of the extremity; limb equilibrates with ambient room temperature.
Rutherford Classification of Acute Limb Ischemia
Class I (Viable) : No sensory loss, no muscle weakness, audible arterial and venous Doppler signals. Emergency revascularization recommended but limb not immediately threatened.
Class IIa (Marginally Threatened) : Minimal sensory loss (toes only), no motor weakness, inaudible arterial Doppler, audible venous Doppler. Requires urgent revascularization within hours.
Class IIb (Immediately Threatened) : Sensory loss extending beyond toes, mild-to-moderate motor weakness (foot drop), inaudible arterial Doppler, audible venous Doppler. Requires immediate emergency revascularization .
Class III (Irreversible) : Profound sensory loss, complete paralysis (rigor), marbled non-blanching skin mottling, inaudible arterial and venous Doppler signals. Primary amputation required ; revascularization contraindicated due to fatal reperfusion syndrome.
- Medical & Revascularization Interventions ACUTE LIMB ISCHEMIA SUSPECTED (6 Ps)
- │
- ▼
- ┌──────────────────────────────────────────────┐
- │ IMMEDIATE THERAPEUTIC HEPARINIZATION │
- │ IV Unfractionated Heparin Bolus (80 units/kg)│
- │ Continuous Drip (Target aPTT 60 - 80 sec) │
- └──────────────────────┬───────────────────────┘
- │
- ▼
- Assess Rutherford Classification
- │
- ┌─────────────────────────┼─────────────────────────┐
- ▼ ▼ ▼
- Rutherford Class I/IIa Rutherford Class IIb Rutherford Class III
- (Viable/Marginally) (Immediately Threatened) (Irreversible Rigor)
- │ │ │
- ▼ ▼ ▼
- Catheter-Directed Emergency Surgical Primary Amputation
- Thrombolysis (CDT) Embolectomy (Fogarty) (Avoid Reperfusion
- or Urgent Angioplasty or Hybrid Thrombectomy Toxicity)
- Immediate Therapeutic Heparinization
Upon initial clinical suspicion of ALI, immediately administer an IV Unfractionated Heparin bolus (80 units/kg) followed by a continuous infusion (18 units/kg/h) targeting a therapeutic aPTT (60-80 seconds) or anti-Xa (0.3-0.7 IU/mL). Heparin prevents microvascular thrombosis propagation and preserves collateral capillary beds.
Catheter-Directed Thrombolysis (CDT)
Technique : A multi-side-hole catheter is navigated intra-arterially directly into the thrombus, delivering a continuous infusion of recombinant tissue plasminogen activator (rtPA / alteplase at 0.5–1.0 mg/h).
Nursing Care & Monitoring : Monitor puncture site for hematoma; perform continuous pulse and neurovascular checks q15-30min; monitor baseline and q6h fibrinogen levels. If fibrinogen drops < 100 - 150 mg/dL, notify physician and prepare to reduce or hold tPA infusion to prevent systemic hemorrhage.
Reperfusion Injury & Compartment Syndrome
Following successful surgical embolectomy or thrombolysis of an acutely ischemic limb, reperfusion triggers secondary tissue complications.
Acute Compartment Syndrome
Pathophysiology : Restoration of blood flow into ischemic tissue leads to hyperosmolar endothelial edema, capillary leak, and massive soft tissue swelling within closed non-compliant fascial compartments of the lower leg.
Clinical Signs : Severe, excruciating pain out of proportion to physical exam , pain exacerbated by passive stretching of calf muscles, firm/tense wooden compartment on palpation, paresthesias.
Diagnostic Threshold : Measurement of intracompartmental tissue pressure > 30 mmHg OR a Delta Pressure (Diastolic BP - Compartment Pressure) < 30 mmHg.
Treatment : Emergency Four-Compartment Surgical Fasciotomy (incisions through anterior, lateral, superficial posterior, and deep posterior compartments).
Systemic Reperfusion Toxicity
Reperfusion flushes intracellular breakdown products accumulated during tissue ischemia into systemic circulation, causing:
Severe Hyperkalemia : Cardiac arrhythmias, peaked T waves, cardiac arrest.
Myoglobinuria & Acute Tubular Necrosis (ATN) : Muscle necrosis releases myoglobin, filtering into renal tubules, forming obstructive casts. Management : Aggressive IV isotonic fluid administration maintaining urine output > 100 - 200 mL/h and urine alkalinization with sodium bicarbonate.